All In Biotech

Drug Trial Radar · NCT03733990

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

216

Actual

Start

Dec 3, 2018

Primary completion

Sep 6, 2023

Study completion Oct 31, 2023

Sponsor

Lead sponsor
Faron Pharmaceuticals LtdIndustry
Sponsor type
Industry
First posted
Nov 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity. The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.

Conditions

  • Cancer

Interventions

  • FP-1305 (bexmarilimab)Biological

    The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT) in the Trial Subjects.Time frame: Up to one year
  2. Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)Time frame: approximately 4 years and 9 months
  3. The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.Time frame: approximately 4 years and 9 months
  4. The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.Time frame: approximately 4 years and 9 months

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Clinical Research Institute HUCH Ltd

    Helsinki, Finland

  • Oulu University Hospital

    Oulu, Finland

  • Tampere University Hospital

    Tampere, Finland

  • Turku University Hospital

    Turku, Finland

  • The Institut Gustave Roussy

    Villejuif, France

  • Erasmus University Medical Center Rotterdam

    Rotterdam, Netherlands

  • START Madrid - CIOCC Hospital HM Sanchinarro

    Madrid, Spain

  • Queen Elizabeth Hospital Birmingham

    Birmingham, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.